• Services
    • Overview
    • Antibody Profiling Solutions
    • Oncology Drug Screening
    • Immunoprofiling
    • Vaccine Development
    • Custom Protein Arrays
  • Applications
        • Disease Area
          • Autoimmune Disease
          • Immuno-Oncology
          • Neurological Disease
          • Infectious Disease
        • Application Area
          • Biomarker Discovery
          • Patient Stratification
          • Disease and Treatment Outcome Prediction
          • Diagnostics & CDx Development
  • Technology
    • Overview
    • KREX Protein Folding Technology
    • Antibodies as Biomarkers
    • Bioinformatics for Antibody Profiling
  • Resources
    • Blog
    • Videos
    • Featured Publications
    • Product Information
    • White Paper & Case Studies
    • Protein List
    • FAQs
  • About
    • Company Overview
      • Patents
    • Meet Our Team
    • News & Events
  • Menu Menu
  • Join Our Team
  • Contact

Code of Conduct

Code of Conduct

Supplier Code of Conduct

View Document

Distributor Code of Conduct

View Document

  • Services
  • Applications
  • Technology
  • Resources
  • About

Sengenics, a functional proteomics company, is committed to advancing precision medicine by empowering researchers with biologically relevant and actionable immunoproteomic insights across a broad spectrum of diseases. At the heart of its mission, Sengenics offers advanced, high-throughput tools using proprietary technology to precisely detect autoantibody biomarkers and protein interactions for basic, translational, and clinical research. Its robust tools have been leveraged by top pharmaceutical companies and leading research institutions to enhance disease understanding and streamline the biomarker pipeline.

© 2024 Sengenics Corporation LLC. All rights reserved. Sengenics Corporation LLC. Registered in Delaware, USA no. 5739583 | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D

Terms & Conditions | Terms of Use | Privacy Statement | Cookie Policy | Code of Conduct | Whistleblowing Policy | Sitemap

Design and development by RainCastle Communications.

"*" indicates required fields

Fill in the form to download the publication

By proceeding, I agree to Sengenics’ Terms of Use and acknowledge that I have read the Privacy Policy.
I also agree that Sengenics or its representatives may contact me by email at the email address I provide, including for marketing purposes.

This field is for validation purposes and should be left unchanged.

"*" indicates required fields

Watch the video

By proceeding, I agree to Sengenics’ Terms of Use and acknowledge that I have read the Privacy Policy.
I also agree that Sengenics or its representatives may contact me by email at the email address I provide, including for marketing purposes.

This field is for validation purposes and should be left unchanged.

"*" indicates required fields

Watch the video

"*" Indicates required fields

By proceeding, I agree to Sengenics’ Terms of Use and acknowledge that I have read the Privacy Policy.
I also agree that Sengenics or its representatives may contact me by email at the email address I provide, including for marketing purposes.

This field is for validation purposes and should be left unchanged.

"*" indicates required fields

Autoantibody-Based Diagnostic Biomarkers: Technological Approaches to Discovery and Validation


Read the Review

By proceeding, I agree to Sengenics’ Terms of Use and acknowledge that I have read the Privacy Policy.
I also agree that Sengenics or its representatives may contact me by email at the email address I provide, including for marketing purposes.

This field is for validation purposes and should be left unchanged.

"*" indicates required fields

Watch the video

By proceeding, I agree to Sengenics’ Terms of Use and acknowledge that I have read the Privacy Policy.
I also agree that Sengenics or its representatives may contact me by email at the email address I provide, including for marketing purposes.

This field is for validation purposes and should be left unchanged.